Collaborations & Alliances

Daiichi Sankyo Terminates Charleston Labs Hydrocodone Pact

Plans to refocus commercial efforts on current product line in the U.S. pain franchise

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Daiichi Sankyo Co., Ltd. has elected to terminate its 2014 development and commercialization agreement with Charleston Laboratories, forgoing further development of Charleston’s hydrocodone products, including CL-108 (hydrocodone, acetaminophen, promethazine) and will be returning all rights to those products to Charleston.   “During a recent portfolio and U.S. market review, Daiichi Sankyo made the strategic decision to refocus our commercial efforts on our current product line in the U...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters